Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Non Operating Income (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Non Operating Income for 13 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 48.13% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, down 8.03% year-over-year, with the annual reading at $7.0 million for FY2025, 8.03% down from the prior year.
  • Non Operating Income hit $1.8 million in Q4 2025 for Coherus Oncology, down from $2.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.9 million in Q2 2025 to a low of -$385000.0 in Q4 2021.
  • Historically, Non Operating Income has averaged $1.2 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Non Operating Income: plummeted 6516.67% in 2021 and later soared 5300.0% in 2023.
  • Year by year, Non Operating Income stood at -$385000.0 in 2021, then skyrocketed by 621.56% to $2.0 million in 2022, then tumbled by 106.42% to -$129000.0 in 2023, then skyrocketed by 1032.56% to $1.2 million in 2024, then skyrocketed by 48.13% to $1.8 million in 2025.
  • Business Quant data shows Non Operating Income for CHRS at $1.8 million in Q4 2025, $2.1 million in Q3 2025, and $2.9 million in Q2 2025.